Sabin Vaccine Institute’s 2019 Annual Report


The Blavatnik Family Foundation is proud to support the Sabin Vaccine Institute and its important work to improve health and save lives around the world.

The Sabin Vaccine Institute’s mission is to make vaccines more accessible, enable innovation and expand immunization across the globe. The 2019 Annual Report highlights their continuing work to develop new vaccines and transform how vaccines reach and are embraced by communities worldwide.

2019 Milestones:

  • The launch of an R&D initiative and licensing promising vaccine candidates

  • Applied insights from immunization professionals on the challenges they face to help shape Boost, a new community for immunization professionals

  • Generating and sharing data on the burden of typhoid to help spur momentum to prevent typhoid and inform national vaccine-introduction decisions

  • Awarded grants to improve vaccine acceptance, supporting research teams in India, Sierra Leone and Uganda

  • Published key recommendations to accelerate the development of a universal influenza vaccine

  • Welcomed four staff to the leadership team, who are directing R&D and community-level efforts, as well as four Board Trustees with expertise spanning vaccines, immunization and global health

  • Fortified and diversified funding base with government, private and institutional support

COVID-19 is demonstrating how unprepared the world is for a pandemic and the central role that vaccines play in protecting families, communities, economies and our social fabric. This follows outbreaks of more than a dozen infectious diseases in 2019, including backsliding on global progress against polio and measles.

Sabin plays a crucial role in connecting the dots between community-level professionals, vaccine scientists, behavioral researchers, health professionals and national and global policy makers to surmount the global health challenges we face today and capitalize on opportunities for progress in the decade ahead.

Make a gift to support the Sabin Vaccine Institute.